Bernard J. Escudier, MD, and Sumanta K. Pal, MD, on RCC: Trial Results on Sunitinib
2017 ASCO Annual MeetingBernard J. Escudier, MD, of Gustave Roussy Cancer Campus, and Sumanta K. Pal, MD, of City of Hope, discuss phase III study findings on adjuvant sunitinib used to treat high-risk renal cell carcinoma, which validate the 16-gene Recurrence Score in patients with stage III disease. (Abstract 4508)
Related Videos
Todd M. Gibson, PhD, on Childhood Cancer Survivors: Chronic Disease Trends
Todd M. Gibson, PhD, of St. Jude Children’s Research Hospital, discusses results from the Childhood Cancer Survivor Study, which showed a reduction in serious chronic morbidity mea...
Nicholas D. James, MBBS, PhD, on Prostate Cancer: Results From the STAMPEDE Trial
Nicholas D. James, MBBS, PhD, of Queen Elizabeth Hospital, discusses study findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-depriva...
Elizabeth R. Plimack, MD, on Advanced Urothelial Cancer: Expert Perspective
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses highlights of three important abstracts on advanced and metastatic urothelial cancer presented at the 2017 ASCO Annu...
Xuesong Han, PhD, on Early-Stage Diagnosis and the Affordable Care Act: An Epidemiologic Study
Xuesong Han, PhD, of the American Cancer Society, discusses the Affordable Care Act and her study findings showing how implementation of the law is associated with a shift to early...
Ronald J. Buckanovich, MD, PhD, on Ovarian Cancer: Expert Perspective on the SOLO2 Trial
Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on health-related quality of life with maintenance olaparib compared with placebo following ...
